Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound
Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound VANCOUVER, British Columbia, 18 December 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a forefront biotechnology company dedicated to revolutionising mental health and addiction treatment, proudly announces the Company has received the issuance of a Notice of Allowance by the United States Patent and Trademark Office (USPTO) for their MYCO-005 compound, "Novel Aza-Substituted Psilocin